Angiotesin II or phenylephrine favour cardiac hypertrophy by inducing NF-kB action: IL-33, by interacting with ST2L, is able to attenuate NF-kB promoter activity and the phosphorylation of IKK [17]. This evidence concerns the gene IL1RL1 and cardiac hypertrophy.